Your browser is out of date!

You are accessing this website using a legacy browser. You may find that certain parts of the new GP Website do not work as expected. We recommend upgrading your browser to continue.

If you are based within a GP practice please contact the GPIT Helpdesk on 020 3816 3258 or email nelondonicb.cahpractitioners@nhs.net to carry out the upgrade

Update on DXA reporting and treatments for osteoporosis

Add to CPD Start a discussion

Book Now

You must be logged in to your account in order to register for this event.

Register

or

Sign In

Update on DXA reporting and treatments for osteoporosis

  • Friday, 28th March 2025, 1.00pm – 2.00pm
  • Online Event

The treatment pathway for postmeonopausal women with osteoporosis has changed with the emergence of two new anabolic treatments approved by NICE (romosozumab and abaloparatide). This teaching will educate practitioners about which patients should be considered for these treatments over oral bisphosphonates.

Speakers:

Dr Vera Choida

Sessions

Update on DXA reporting and treatments for osteoporosis — Afternoon

Friday, 28th March 2025 / 1.00pm

As above

 

You're adding a event to your CPD log. The title of this entry will be Update on DXA reporting and treatments for osteoporosis. You can change the description, reflection or CPD Credit Hours at any time from within My CPD

Add to CPD

When you attend an event booked through the North East London ICB (City & Hackney) GP Website, we'll add the event details to your CPD section automatically.

External Link

This is an external link. Continuing will take you away from the North East London ICB (City & Hackney) GP Website. Please be aware that some external resources may be restricted to NHS Secure Network connections only.

Continue

Page Feedback

Report a problem or suggestion using this facility. When describing your problem or suggestion, be as descriptive as possible and include any specific error messages you may see.

Please note

This website is for healthcare professionals only. It is not intended for public use.

Continue